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Background:  Estimates  of WHO  and  UNICEF  vaccination  coverage  may  provide  little  insight  into  the extent
to which  vaccinations  are  administered  on time.  Yet,  lack  of  adherence  to the  recommended  age  to
receive  a speciﬁc  vaccination  may  have  detrimental  health  consequences.  For  example,  delays  in receiving
vaccination  will  prolong  the  risk  of lack  of  protection,  often  when  disease  risk  is  highest,  such  as  during
early  infancy.  We  estimated  the  reported  age  at vaccination,  and  vaccine  coverage  at different  ages  in
children  from  ﬁve  sub-Saharan  African  countries.
Methods:  We  analyzed  data  from  the  latest  Demographic  and  Health  Programme  databases  available  for
Burkina  Faso  2010  (n =  15,044  observations),  Ghana  2008  (n = 2992),  Kenya  2008–9  (n  = 6079),  Senegal
2010–11  (n = 12,326),  and  Tanzania  2010  (n =  8023).  We  assessed,  amongst  vaccinees,  the  exact  age  when
vaccine  was  administered  for the  three  infant  doses  of  pentavalent  vaccine  (DTP)  and  the  ﬁrst  dose  of
measles-containing-vaccine  (MCV),  as  well  as  the proportion  of  children  immunized  with  these  antigens
by  a certain  age.  Vitamin  A  supplementation  (VAS)  coverage  was  evaluated  as  a  potential  contact  visit
for  vaccine  introduction.
Results: For  all  DTP  doses,  the median  intervals  between  recommended  and  actual  ages  of  receiving
vaccination  ranged  from  12, 17  and  23  days  in Kenya,  to  22,  33  and  45  days  in Senegal.  MCV  was  mostly
given  during  the  recommended  age of 9 months.  In  each  country,  there  was  a large  discrepancy  in  the
median  age  at  DTP  vaccination  between  regions.  VAS  coverage  in  young  children  ranged  from  30.3%  in
Kenya  to 78.4%  in Senegal,  with  large  variations  observed  between  areas  within  each  study  country.
Conclusion:  In  the context  of new vaccine  introduction,  age  of  children  at vaccination  should  be monitored
to  interpret  data  on  vaccine-preventable  disease  burden,  vaccine  effectiveness,  and  vaccine  safety,  and
to adapt  targeted  interventions  and  messages.
ublis© 2015  The  Authors.  P
. IntroductionAs a result of the strengthening of the Expanded Programme on
mmunization (EPI) starting four decades ago, and more recently
ith the support of Gavi, the Vaccine Alliance (formerly the
Abbreviations: DHS, Demographic and Health Surveys; DTP, diphtheria, pertus-
is,  and tetanus; DTwP, diphtheria, tetanus, and whole-cell pertussis; EPI, Expanded
rogramme on Immunization; hepB, hepatitis B; Hib, Haemophilus inﬂuenzae type
;  IQR, interquartile range; MCV, measles-containing vaccine; PCV, pneumococcal
onjugate vaccine; UNICEF, United Nations Children’s Fund; VAS, vitamin A supple-
entation; WHO, World Health Organization; YFV, yellow fever vaccination.
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y-nc-nd/4.0/).hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Global Alliance for Vaccines and Immunization), global child deaths
from vaccine-preventable diseases have dramatically decreased in
Africa. In addition to the large impact of measles vaccination on
child survival [1], these advances are also due to the introduction
of ﬁve new vaccines to national vaccination plans (i.e., vaccines
against Haemophilus inﬂuenzae type b, hepatitis B virus, pneumo-
coccus, rotavirus, and meningococcus A), and to the reinforcement
of vaccine implementation strategies and monitoring, driven by the
World Health Organization (WHO) and the United Nations Chil-
dren’s Fund (UNICEF). The possible introduction of a vaccine against
malaria in the coming years may  further improve child health and
survival in malaria endemic areas.
In the context of vaccine evaluation, the design of effectiveness,
post-introduction impact, and safety studies depends on vacci-
nation coverage and timeliness data. Vaccination coverage rates
are often estimated based on programmatic data (i.e., by dividing
the number of doses distributed or administered by the estimated
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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We  used the DHS Programme STATcompiler tool version1.5.2
[27] to generate descriptive data within various stratiﬁcation cat-
egories. We  calculated age at DTP and measles vaccination byI. Delrieu et al. / Vacc
arget population sizes). The resulting estimations may  be unre-
iable where the target population size is poorly known [2], or
hen only the distributed doses are reported. To mitigate this
ssue, WHO-UNICEF currently emphasizes the need for more pre-
ise estimates combining various sources of information: reports
y national authorities, survey data, and views of local country
xperts [3]. In addition to precisely deﬁning coverage, age at vac-
ination is important to assess the performance of a vaccination
rogramme, and previous studies document that high coverage
oes not necessarily imply timely vaccination [4,5]. Substantial
hildhood vaccinations delays were described in low-to-middle [6],
nd high income countries [7–9]. African children may  also expe-
ience a gap between recommended and actual vaccine schedules
10]. Published analyses have revealed that adherence to recom-
ended schedules varies substantially within and between African
ountries [6,10–14], a ﬁnding conﬁrmed by recent manuscripts
15–18].
Delays in receipt of speciﬁc doses or completing a childhood
accination series could beneﬁt an individual child by inducing
 stronger immune response, ensuring a prolonged duration of
rotection. However, regardless of completion of the full sched-
le, children with delayed vaccination, experience longer periods
f increased susceptibility to the vaccine preventable disease, as
eported for pertussis [19] or Haemophilus inﬂuenza type b (Hib)
nvasive disease [20]. In addition, delay at vaccination may  raise
afety concerns depending on the age related risk of adverse events,
s exempliﬁed by the RotaShieldTM (Wyeth-Ayerst, Philadelphia,
A, USA) vaccination against rotavirus, that was associated with an
ncreased intussusceptions risk among children age greater than 12
eeks [21]. Policy decision makers recommend schedules by trying
o balance duration of immunity with period of risk assuming that
hildren will receive vaccine at the recommended age.
In sub-Saharan Africa, recent vaccines such as rotavirus vaccine
RotaTeqTM and RotarixTM), pneumococcal conjugate vaccine (PCV)
Prevnar-13TM and SynﬂorixTM), and serogroup A meningococcal
onjugate vaccine (MenAfriVacTM) were designed to protect infants
nd young children when administered between 6 weeks and 2
ears of age, depending on the vaccine. The RTS,S/AS01 malaria
accine candidate may  be integrated into the national vaccine pro-
ramme  of sub-Saharan African countries, either with a primary
eries of three doses concurrent with diphtheria, tetanus, and per-
ussis (DTP) containing vaccines during early infancy or starting in
hildren between 5 and 17 months of age [22].
In this article, we estimated the reported age at vaccination,
nd vaccine coverage at different ages in children from the ﬁrst
ve sub-Saharan African countries where the RTS,S/AS01 candidate
alaria vaccine may  be introduced, namely Burkina Faso, Ghana,
enya, Senegal and Tanzania. These countries have been identi-
ed as early adopters because they represent a broad spectrum
f malaria endemicity and each has the capacity to perform vac-
ine safety evaluations. To evaluate the potential deviation from
he age recommended for vaccination within the EPI schedule, we
nalyzed age at vaccination and administration of the three primary
oses of DTP combined with hepatitis B (hepB) and Hib conjugate
accine (abbreviated as DTP1, DTP2 and DTP3), as well as measles-
ontaining vaccine (MCV).
An earlier analysis provided data on immunization delays glob-
lly during 1996–2005 [10]. Our study advances beyond this
y including more recent data, a critical issue given the large
nvestments made in improving immunization services, includ-
ng in Africa. Additionally, we considered sub-national delays in
mmunization, since immunization service delivery may  vary con-
iderably within African countries. Lastly, current international
ecommendations call for children age 6–59 months living in high
isk areas to receive a single dose of yellow fever vaccination
YFV) introduced into routine immunization programmes, and one (2015) 7290–7298 7291
dose of Vitamin A supplementation (VAS) in children from 6 to 11
months and every 4–6 months in children 12–59 months of age
[23]. Consequently, we also investigated timeliness for YFV visits,
and coverage for VAS contacts, as they may  serve as contacts for
new vaccine interventions.
2. Methods
We used publically available data from the programme Demo-
graphic and Health Surveys (DHS),1 which generates data from
nationally representative household surveys [24]. The standard
DHS have large sample sizes and use a two-stage sampling design,
with a ﬁrst selection of primary clusters from a list of enumeration
areas, followed by a second random selection of households from
each cluster [25]. Eligible women of reproductive age are inter-
viewed using an individual standard questionnaire and asked to
show the health cards of their children born in the 5 years before the
survey to document the date each vaccine dose was  administered.
When no card is presented, the mother is asked to recall vaccina-
tions dates. An analysis of retrospective data was conducted from
the latest standard DHS surveys databases available for the ﬁve
study countries: Burkina Faso 2010, Ghana 2008, Kenya 2008–9,
Senegal 2010–11 and Tanzania 2010. For each country, the num-
bers of children aged 0–5 years born from sub-sampled women,
were 15,044, 2992, 6079, 12,326 and 8023, respectively. We  limited
our analysis to children who  had complete (day, month, year) birth
and vaccination dates recorded on a vaccination card.
For each vaccination dose (DTP1, DTP2, DTP3, MCV, and YFV
when data were available), we estimated the mean, median and
interquartile ranges (IQRs) for age at vaccination in each study
country. WHO  does not have a universal, biologically deﬁned sched-
ule for DTP immunization, but rather provides recommendation on
appropriate ranges. Consequently, we  created a reference standard
based on each country’s national programmatic standards. For
DTP1, DTP2, and DTP3 vaccinations, this included: days 56, 84
and 112 in Burkina Faso; days 42, 70 and 98 in Ghana, Kenya and
Senegal; and days 28, 56 and 84 in Tanzania. For MCV-related cal-
culations, we used when the child was  age 9 months (i.e., the 10th
month of life or 274–304 days as a reference. We  calculated the time
interval between the observed age at vaccination and the reference
date recommended for vaccination. The ages for vaccination were
converted to days based on 30.4375 days per month. In each coun-
try, medians and percentile (25th and 75th) durations before and
after the reference dates were determined for each vaccine dose,
and the numbers and proportions of children vaccinated outside
the reference dates were calculated.
For analysis, we  used the sampling weights provided in each
DHS dataset to extrapolate sample data to the entire population
of each country. To adjust for clusters and strata, the survey design
applied considered the following variables: sample weight, primary
sampling unit, type of place of residence (urban/rural) and region.
For vaccination dose uptake estimation, we  used the Kaplan Meyer
survival analysis method to describe time-to-event data [7,26].
Children with missing dates of vaccination were excluded from
individual analyses. For children with valid dates for birth and vac-
cination, we calculated coverage at age-appropriate time points,
and ages at which 95% and 99% of vaccinated children received
their injection.administrative region within each country. We calculated DTP and
1 For more information on the DHS programme, see http://dhsprogram.com/.
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CV  coverage by source of information (vaccination card, mother’s
eport and either source). Lastly, we calculated VAS coverage by
dministrative region and child’s age at interview. From the original
HS programme databases, we extracted data and created work-
ng databases to perform our statistical analyses using Stata v.10
oftware (StataCorp LP, College Station, Texas, USA). The “rcentile”
ackage (www.imperial.ac.uk/nhli/r.newson/stata.htm) was used
o calculate robust conﬁdence intervals for percentiles, allowing
or clustered sampling and weighting.
. Results
.1. Median age at vaccination
In Kenya, Ghana, and Senegal, the recommended age at DTP1
accination was 42 days and the actual median estimates were 48,
6, and 59 days, respectively; DTP2 was scheduled at 70 days and
as given at median ages of 82, 92, and 98 days, respectively; and
TP3 was recommended at 98 days, and median ages were 115,
28, and 137 days, respectively (Table 1). In Burkina Faso, where
TP doses were to be received at 56, 84, and 112 days, estimated
edian ages for DTP doses were 66, 101, and 137 days, while in
anzania, where DTP doses were scheduled at 28, 56 and 84 days,
edian ages at vaccination were 44, 83, and 123 days. In all ﬁve
ountries, measles vaccination was mostly given within the rec-
mmended age of 9 months (i.e., before the 10th month of age),
ith the median age at MCV  injection ranging from 274 to 305
ays. Where YFV was listed in the DHS Programme databases (Bur-
ina Faso, Kenya, and Senegal), the median age at injection was
onsistent with the recommended age of 9 months.
Within countries, substantial variation in age of DTP vaccination
as seen but not for MCV  (Appendix Tables A1 to A5). The highest
ariations were described for DTP3, with differences between the
able 1
stimates of age at vaccination for DTP1, DTP2, DTP3, measles and yellow fever vaccines 
Burkina Faso 2010 Gha
DTP1 vaccination
Reference date 56 days 42 d
Children with DTP1 done 12,027 249
Children with accurate age at vaccination for DTP1 4430 184
Mean age (St. Err.) 75.27 (0.83) 68.
Median age (IQR) 66 [60–79] 56 
DTP2  vaccination
Reference date 84 days 70 d
Children with DTP2 done 11,571 234
Children with accurate age at vaccination for DTP2 4227 177
Mean age (St. Err.) 113.03 (1.01) 110
Median  age (IQR) 101 [92–119] 92 
DTP3  vaccination
Reference date 112 days 98 d
Children with DTP3 done 10,861 209
Children with accurate age at vaccination for DTP3 4034 167
Mean age (St. Err.) 153.62 (1.34) 152
Median  age (IQR) 137 [124–162] 128
Measles  vaccination
Reference date 9 months = 274–304 days
Children with MCV  done 9845 204
Children with accurate age at vaccination for MCV  3445 144
Mean age (St. Err.) 299.47 (1.79) 316
Median  age (IQR) 284 [273–304] 294
Yellow  fever vaccination
Reference date 9 months = 274–304 days
Children with YF done 6922 na 
Children with accurate age at vaccination for YF 3450 na 
Mean age (St. Err.) 300.04 (1.78) na 
Median age (IQR) 284 [273–304] na 
ata are calculated from the latest available DHS programme databases. Reference dates  (2015) 7290–7298
reference date of vaccination and the actual injection varying by 53
days between regions, both in Ghana (from 23 days difference in
Brong-Ahafo to 76 days in the Northern region), and in Kenya (from
7 days in Central to 60 days in North Eastern regions).
3.2. Deviations from recommended schedules
We  estimated the difference in days before and after the ref-
erence dates for DTP1, DTP2, DTP3, and MCV  (Table 2). Among
vaccinees receiving their DTP dose after the reference day, depend-
ing on the country, the median time interval ranged from 12 to 22
days for DTP1, from 17 to 33 days for DTP2, and from 23 to 45
days for DTP3. For all doses, the shortest median time interval was
always observed in Kenya, while the highest was observed in Sene-
gal (Table 2). A quarter of the children received DTP1 injection nine
days or less after the reference date, DTP2 two  weeks or less after
the reference date, and DTP3 3 weeks or less after the reference
date. In Senegal, where time intervals were the greatest, 75% DPT1
coverage was achieved at 47 days after the reference date; for DTP2
and DTP3, 75% coverage was  attained at 67 and 96 days, respec-
tively. In all countries, median time intervals were approximately
twice as long for DTP3 as for DTP1. For vaccinees receiving DTP
vaccination before the reference date, median early deliveries were
similar for all doses in all countries (7 days for DTP1 in Senegal and
for DTP3 in Ghana and Kenya, and up to 12 days for DTP3 in Senegal).
For MCV, among the 34% of children vaccinated after age 9
months (i.e., after day 304 of life), half had time intervals of two
months or more (61 ± 3 days in Burkina Faso, Ghana and Tanzania;
76 days in Kenya and Senegal). The 75th percentile delays were
99 days in Burkina Faso and up to 170 days in Kenya. Unlike with
DTP, Kenya had the longest median delay for MCV. For vaccinees
receiving MCV  early, 75% were vaccinated when they were age 8
months.
in the ﬁve study countries.
na 2008 Kenya 2008–09 Senegal 2010–11 Tanzania
ays 42 days 42 days 28 days
4 5034 10,132 6878
2 3076 1702 5207
79 (1.74) 65.34 (2.38) 75.16 (2.16) 60.86 (na)
[45–72] 48 [43–65] 59 [46–80] 44 [34–64]
ays 70 days 70 days 56 days
6 4706 9498 6521
2 2932 1574 4958
.72 (2.23) 101.51 (2.53) 119.23 (2.99) 106.08 (na)
[79–116] 82 [73–105] 98 [80–129] 83 [67–113]
ays 98 days 98 days 84 days
8 4121 8572 6088
7 2679 1444 4660
.96 (2.45) 139.41 (2.82) 170.30 (4.21) 152.25 (na)
 [112–161] 115 [104–145] 137 [114–186] 123 [101–166]
2 3964 8348 5404
6 2124 1160 3910
.02 (3.1) 317.89 (4.68) 327.57 (6.61) 320.12 (na)
 [276–321] 287 [275–318] 288 [274–330] 295 [280–325]
na 8161 na
182 1144 na
334.12 (na) 333.9 (6.83) na
290 [252–347] 290 [276–331] na
for vaccination are in italics.
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Table 2
Duration between reference day of vaccination and actual injection, before and after the reference date: 25th, 50th and 75th percentile duration, by country.
Vaccines Delays
percentiles
and IQR
Burkina Faso Ghana Kenya Senegal Tanzania
Time  to the vaccination
(in days)
Time to the vaccination
(in days)
Time to the vaccination
(in days)
Time to the vaccination
(in days)
Time to the vaccination
(in days)
Before
reference
date
After
reference
date
Before
reference
date
After
reference
date
Before
reference
date
After
reference
date
Before
reference
date
After
reference
date
Before
reference
date
After
reference
date
DTP1 Reference
date
56 days 42 days 42 days 42 days 28 days
(Nt);  (Nb);
(Na)
(4430) (648) (3709) (1842) (216) (1554) (3076) (555) (2281) (1702) (223) (1459) (5207) (261) (4893)
25th  19 6 20 9 17 4 18 8 19 9
50th  11 13 8 19 7 12 9 22 9 20
75th  6 26 3 36 3 31 3 47 3 38
IQR  13 20 17 27 14 27 15 39 16 29
DTP2  Reference
date
84 days 70 days 70 days 70 days 56 days
(Nt);  (Nb);
(Na)
(4227) (438) (3748) (1772) (147) (1589) (2932) (409) (2399) (1574) (120) (1439) (4958) (151) (4787)
25th  17 10 16 14 19 6 22 15 18 15
50th  10 19 9 26 8 17 10 33 10 30
75th  5 37 4 51 3 41 5 67 3 57
IQR  12 27 12 37 16 35 17 52 15 42
DTP3  Reference
date
112 days 98 days 98 days 98 days 84 days
(Nt);  (Nb);
(Na)
(4034) (302) (3701) (1677) (89) (1562) (2679) (289) (2317) (1444) (78) (1352) (4660) (95) (4558)
25th  15 14 16 18 17 9 20 22 21 21
50th  11 27 7 35 7 23 12 45 11 41
75th  5 51 3 72 4 54 4 96 4 80
IQR  10 37 13 54 13 45 16 74 17 59
Measles  Reference
date
9 months = 274–304 days 9 months = 274–304 days 9 months = 274–304 days 9 months = 274–304 days 9 months = 274–304 days
(Nt);  (Nb);
(Na)
(3445) (873) (843) (1446) (296) (546) (2126) (514) (683) (1160) (254) (433) (3910) (534) (1546)
25th  20 40 31 42 34 44 30 45 26 44
50th  8 58 15 62 16 76 11 76 12 64
75th  4 99 6 128 5 170 5 156 4 111
IQR  16 59 25 86 29 126 25 111 22 67
Reference days and percentile difference from recommended date, are in days. The total number of vaccinees for a speciﬁc dose (Nt), the number of vaccinees vaccinated before (Nb) and after (Na) the reference date are indicated.
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.3. Coverage by age among vaccineesUsing DHS data, and based on both vaccination cards and
other’s report, we found that the proportion of 12–23 month
ld children vaccinated with DTP1 and DTP2 at any time before
he survey was over 90%. In the same population, DTP3 coverage
ig. 1. Inverse Kaplan–Meyer estimate for DTP and measles vaccination coverage: (A
inees  receiving vaccine by the recommended age (for MCV, two lines represents
hich  50% of vaccinees are vaccinated. In blue, age at which 95% and 99% of vacci
III)  Kenya; (IV) Senegal and (V) Tanzania. (For interpretation of the references to c
rticle.) (2015) 7290–7298
ranged from 83% in Senegal to nearly 90% in Burkina Faso. MCV
coverage ranged from 82% in Senegal to 90% in Ghana (Table A6 in
Appendix).
Among vaccinated children for whom a precise date of vacci-
nation is available, the percent of children who had received DTP
vaccine by the recommended date for each dose was relatively
) DTP1; (B) DTP2; (C) DTP3; (D) MCV. Footnote: In bold red, percent of vac-
 the lowest and highest boundaries of the 10th month), and in red, age at
nees received vaccination. Coverage are given for (I) Burkina Faso; (II) Ghana;
olour in this ﬁgure legend, the reader is referred to the web version of this
I. Delrieu et al. / Vaccine 33 (2015) 7290–7298 7295
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3.4. Vitamin A administrationFig. 1. 
ow and varied by country (Fig. 1I–V): from 6.5%, 3.5%, and 2.3% in
anzania, to 24%, 18%, and 13% in Kenya, for DTP1-3, respectively.
y the end of the 10th month, over 60% of vaccinees had received
CV  (from 61% in Tanzania to 75% in Burkina Faso). The mediange in days at which 95% of vaccinees had received the four dif-
erent study vaccines was highest in Senegal at 166, 247, 355 and
00 days for DTP1-3 and MCV, respectively; while the earliest wasinued).
reached in Burkina Faso, at 127, 185, 259, and 393 days for DTP1-3
and MCV, respectively.VAS coverage was  described in the study countries using the lat-
est DHS data (Table 3). The lowest coverage was observed in Kenya
7296 I. Delrieu et al. / Vaccine 33 (2015) 7290–7298
Table  3
Vitamin A supplement intake coverage, by children age group at interview.
Demographic & Health Survey Vitamin A supplement intake coverage Total
Children age group at interview (in months)
6–9 10–11 12–23 24–35 36–47 48–59
Burkina Faso 2010 61.6 (1015) 72.7 (473) 66.7 (2822) 64.5 (2729) 61.3 (2821) 57.9 (2613) 63.0 (12,473)
Ghana  2008 72.3 (191) 74.6 (111) 67.0 (552) 52.8 (496) 49.3 (506) 43.9 (559) 55.8 (2414)
Kenya  2008–09 46.7 (419) 60.9 (187) 40.9 (1096) 25.9 (1132) 21.8 (1071) 20.4 (1041) 30.3 (4946)
Senegal 2010–11 66.4 (690) 75.4 (409) 81.2 (2199) 80.0 (2195) 77.9 (2234) 78.7 (1963) 78.4 (9689)
Tanzania 2010 42.4 (499) 65.0 (302) 67.4 (1576) 60.5 (145) 60.9 (1567) 59.2 (143) 60.8 (6824)
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Aercentage and number of children aged 6–59 months who  received vitamin A supp
ww.statcompiler.com  – March 24, 2015.
009 with 30.3% of children under age ﬁve years supplemented dur-
ng the 6 months preceding the survey; and the highest described
n Senegal 2010–2011 with 78.4% coverage. In all countries,
hildren less than 2 years old were more likely to have received
AS. In Burkina Faso, Ghana and Kenya, children were the most
ikely to have received VAS within the ﬁrst year of life, with 72.7%,
4.6% and 60.9%, respectively. In Senegal and Tanzania, the highest
AS coverage was reported for the 6–23 month age group (12–23
onths at interview), with 81.3% and 67.4% coverage, respectively.
arge variations in VAS coverage were observed within each study
ountry, depending on region and type of residence of the chil-
ren, with the highest difference described in Tanzania (nearly
0% difference between Shinyanga and Iringa), and Burkina Faso
54% difference between Sahel and Centre Sud) (Table A7 to A11 in
ppendix).
. Discussion
In our study population, we showed high vaccine coverage
mong infants and young children in ﬁve sub-Saharan African
ow-income countries. We  showed a global trend towards adminis-
ration of DTP3 and measles vaccination beyond the recommended
ge. A similar pattern has been described for other sub-Saharan
ettings, including Kenya, South Africa, Uganda, Malawi, Nigeria,
anzania, and The Gambia [13–15,28–31]. While the data derive
rom different areas and use different methods, as a whole, and in
ombination with our study, they indicate a long-standing issue
ith timely infant vaccination in sub-Saharan Africa. The degree to
hich this low compliance to schedules occurs has varied within
nd between countries [6,10]. Our results also showed regional dis-
arities of vaccination timeliness, with Ghana and Kenya displaying
he largest variations.
Several factors might explain the variation observed, such as
ncreasing distance to the clinic, immunization administration out-
ide a health facility [30,32–35], and low health worker density
36]. Rural areas, often with limited health services, may  have popu-
ations who are less compliant to schedules than urban populations.
or example in Ghana, rural areas [16] had longer delays from rec-
mmended schedules than urban areas [35]. Even within a rural
rea, such as rural Malawi, more remote settings with no access
o vaccination teams had poorer compliance [32]. Childhood vac-
ination is often conducted via outreach by public health nurses
here all children in a village receive their dose on the same day,
ossibly leading to age-inappropriate vaccinations. However, the
eneralization of increased risk in rural areas is not universal. Rural
hildren in Burkina Faso had timelier receipt of vaccination than
rban children, probably due to greater access to mobile vaccina-
ion teams [17]. Compliance to schedules may  also be less among
hildren of lower socioeconomic status and born to less educated
others, as has been shown in Senegal [37], Ghana [16], Bur-
ina Faso [17], Malawi [30], Uganda [34], Tanzania [14], and South
frica [28]. Another signiﬁcant known predictor of timely vaccinets in the six months preceding the surveys. DHS Programme STAT compiler, http://
coverage is seasonality, with delays observed during the rainy sea-
son [13,32]. In addition, it was  reported that delays in previous
vaccinations increased the likelihood of further delays in later vac-
cinations [15,31].
In theory, new interventions, such as use of malaria vaccine out-
side of routine infant DTP schedules, could take advantage of other
interventions such as VAS. However, we  found that VAS coverage
is relatively low, higher in urban zones, and with large variations
within and between countries. To result in a measurable impact
on child survival at the population level, at least 80% of children
in this age group should receive VAS twice a year [38], with an
optimal interval between two VAS doses of four to six months
[39]. Even after several years of implementation, VAS programmes
still depend on opportunistic contacts (measles vaccination,
National Immunization Days for polio eradication, multi-antigens
catch-up campaigns), or on National Child Health Days as key
delivery mechanisms. Incorporation of additional routine inter-
ventions into the VAS encounter thus will require additional
investment including increased human resources and sustainable
ﬁnancing. In addition, this will require a commitment by countries
to incorporating immunization into routine encounters outside of
infancy.
Our study had limitations. Only children with a vaccination
card available were included and they do not represent all chil-
dren within the surveyed communities, as these children may
be more likely to have received timely vaccination. We  also did
not assess reasons why  vaccinations were delayed. This infor-
mation could improve performance of vaccination programmes,
helping them to focus on sub-populations with increased risk of low
compliance.
Our study leads to several recommendations. As with vaccina-
tion coverage, levels of poor compliance to vaccination schedules
likely will vary by time and place, and monitoring of vaccination
schedule should be incorporated into routine programme manage-
ment. Speciﬁc community-based contextual information should
be investigated to explain low levels of timely vaccination, since
this can assist with identifying proﬁles for at-risk populations,
and thus facilitate social messaging and other targeted interven-
tions. Any interventions should consider previous ﬁndings showing
that restricting the age for vaccination may  decrease coverage by
increasing missed opportunities for vaccination [40]; this is par-
ticularly true since achieving full vaccination, even if delayed, is
likely to be of more public health value than timely but incom-
plete vaccination receipt. Emphasis on vaccine timeliness may
have the unintended consequence of increasing the number of
doses given too early, which could manifest as vaccines given
at an age when immune responses are less (especially the ﬁrst
dose) or with an interval too short to optimize the booster effect.
Lastly, our ﬁndings have implications for using existing inter-
vention schedules for new vaccines, particularly during impact
evaluations. Speciﬁcally, in addition to coverage, actual age of vacci-
nation should be monitored to interpret results related to measured
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